3AC Stock Overview A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Actinogen Medical Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Actinogen Medical Historical stock prices Current Share Price AU$0.014 52 Week High AU$0.054 52 Week Low AU$0.012 Beta 1.26 1 Month Change 3.70% 3 Month Change -24.32% 1 Year Change 12.00% 3 Year Change -83.13% 5 Year Change -17.65% Change since IPO -75.86%
Recent News & Updates
Actinogen Randomizes First US Participant in Xanamia Phase 2B/3 Alzheimer's Disease Trial Dec 10
Actinogen Medical Appoints Andrew Udell as Chief Commercial Officer Oct 29 Actinogen Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Oct 10
Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024 Sep 25
New minor risk - Financial position Sep 03
Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial Aug 26 See more updates
Actinogen Randomizes First US Participant in Xanamia Phase 2B/3 Alzheimer's Disease Trial Dec 10
Actinogen Medical Appoints Andrew Udell as Chief Commercial Officer Oct 29 Actinogen Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million. Oct 10
Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024 Sep 25
New minor risk - Financial position Sep 03
Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial Aug 26
Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial Aug 13
New minor risk - Market cap size Aug 12
Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker Jun 27
New major risk - Revenue and earnings growth May 17 Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial Apr 15
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial Nov 29
Actinogen Medical Limited Announces CFO Changes Nov 08
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston Oct 14
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results Sep 27
New minor risk - Shareholder dilution Sep 11
Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023 Aug 31
New minor risk - Financial data availability Aug 25
New major risk - Financial position Jul 03
Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention Jun 01
Actinogen Medical Limited Announces Executive Changes Feb 01
Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial Dec 22
Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial Dec 16
Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial Dec 08
MD, CEO & Director recently bought €60k worth of stock Nov 05
Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results Oct 10
Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022 Aug 26
Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression Jun 15
Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD Jun 14
MD, CEO & Director recently bought €85k worth of stock May 14
Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem Apr 28
Actinogen Medical Limited Announces Executive Changes Feb 15
Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1 Feb 11
Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants Nov 29
Actinogen Medical Limited Completes Global Patent Family Grant Aug 25
Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial Jul 15
Actinogen Receives Positive Pre-IND FDA Advice for FXS Jun 24
Actinogen Medical Receives Ethics Committee Approval for XanaMIA study Jun 02
Actinogen Medical Limited Appoints Steven Gourlay as CEO Mar 15
MD, CEO & Director John Ketelbey has left the company Feb 10
MD, CEO & Director John Ketelbey has left the company Feb 09 Actinogen Medical Limited Announces Executive Changes
Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome Feb 05
Actinogen Medical Limited Announces Two New Clinical Trials Oct 15
Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer Sep 28
Earnings released Aug 27 Shareholder Returns 3AC DE Biotechs DE Market 7D 3.7% -0.8% -1.6% 1Y 12.0% -13.0% 6.8%
See full shareholder returns
Return vs Market: 3AC exceeded the German Market which returned 6.8% over the past year.
Price Volatility Is 3AC's price volatile compared to industry and market? 3AC volatility 3AC Average Weekly Movement 23.9% Biotechs Industry Average Movement 6.9% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 3AC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3AC's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials, that achieves target engagement in the brain for the treatment of Alzheimer’s disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015.
Show more Actinogen Medical Limited Fundamentals Summary How do Actinogen Medical's earnings and revenue compare to its market cap? 3AC fundamental statistics Market cap €44.25m Earnings (TTM ) -€7.83m Revenue (TTM ) €5.96m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 3AC income statement (TTM ) Revenue AU$9.93m Cost of Revenue AU$0 Gross Profit AU$9.93m Other Expenses AU$22.98m Earnings -AU$13.04m
Last Reported Earnings
Jun 30, 2024
Earnings per share (EPS) -0.0042 Gross Margin 100.00% Net Profit Margin -131.34% Debt/Equity Ratio 0%
How did 3AC perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/25 14:13 End of Day Share Price 2024/12/23 00:00 Earnings 2024/06/30 Annual Earnings 2024/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Actinogen Medical Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Tara Speranza Bell Potter Pooya Hemami Edison Investment Research
Show 0 more analysts 
